Table 1 Characteristics of patients according to outcome
Variables | Total (n = 170) | Survivors (n = 132) | Death (n = 38) | P |
|---|---|---|---|---|
Age (day), M (IQR) | 84 (49, 151) | 84 (50, 161) | 83 (48, 146) | 0.599 |
Gender (male), n(%) | 90 (52.94) | 74 (56.06) | 16 (42.11) | 0.129 |
Immunization, n(%) | 76 (44.71) | 59 (44.70) | 17 (44.74) | 0.997 |
WBC (× 109/l),M (IQR) | 32.77 (17.68, 58.25) | 28.41 (16.01, 47.36) | 67.31 (29.31, 92.76) | <.001 |
Lymphocytic absolute value, M (IQR) | 15.18 (7.68, 27.20) | 14.62 (7.22, 24.04) | 24.47 (9.79, 32.10) | 0.034 |
Neutrophils absolute value, M (IQR) | 13.62 (7.20, 23.83) | 11.61 (6.37, 19.13) | 29.95 (14.52, 49.94) | <.001 |
Monocytes absolute value, M (IQR) | 1.44 (0.73, 2.80) | 1.23 (0.70, 2.15) | 2.90 (1.25, 4.87) | <.001 |
PLT (× 109/l), M (IQR) | 565 (466, 708) | 584 (481, 715) | 524 (330, 666) | 0.021 |
CRP (mg/l), M (IQR) | 8 (8, 22) | 8 (8, 14) | 29 (8, 45) | <.001 |
PCT (ng/ml), M (IQR) | 0.11 (0.07, 0.31) | 0.10 (0.07, 0.18) | 0.22 (0.11, 0.63) | <.001 |
Bilirubin (μmol/l), M (IQR) | 6.50 (2.00, 13.68) | 6.00 (1.90, 12.07) | 9.30 (4.20, 21.92) | 0.035 |
Creatinine (μmol/l), M (IQR) | 21.50 (17.52, 25.48) | 21.00 (17.90, 25.20) | 22.20 (16.00, 26.30) | 0.830 |
ALT (U/L), M (IQR) | 34.00 (23.85, 47.00) | 33.15 (23.60, 46.00) | 37.70 (26.10, 53.85) | 0.205 |
PCO2(mmHg), M (IQR) | 43.30 (37.00, 52.00) | 43.00 (37.00, 49.60) | 50.75 (40.25, 56.90) | 0.050 |
PO2(mmHg), M (IQR) | 86.40 (65.03, 118.50) | 86.60 (65.07, 111.25) | 85.00 (65.25, 148.00) | 0.440 |
PH, n(%) | 18 (10.59) | 16 (12.12) | 2 (5.26) | 0.362 |
Epilepsy, n(%) | 8 (4.71) | 7 (5.30) | 1 (2.63) | 0.802 |
Hypoproteinemia, n(%) | 74 (43.53) | 58 (43.94) | 16 (42.11) | 0.841 |
Sepsis, n(%) | 27 (15.88) | 12 (9.09) | 15 (39.47) | <.001 |
Shock, n(%) | 32 (18.82) | 8 (6.06) | 24 (63.16) | <.001 |
Respiratory failure, n(%) | 164 (96.47) | 128 (96.97) | 36 (94.74) | 0.874 |
ARDS, n(%) | 12 (7.06) | 3 (2.27) | 9 (23.68) | <.001 |
Myocardial injury, n(%) | 50 (29.41) | 35 (26.52) | 15 (39.47) | 0.122 |
Hepatic injury, n(%) | 34 (20.00) | 24 (18.18) | 10 (26.32) | 0.269 |
AKI, n(%) | 9 (5.29) | 1 (0.76) | 8 (21.05) | <.001 |
Other respiratory pathogen infectionsa, n(%) | 129 (75.88) | 97 (73.48) | 32 (84.21) | 0.173 |
Pneumonia, n(%) | 165 (97.06) | 127 (96.21) | 38 (100.00) | 0.501 |
Atelectasis, n(%) | 66 (38.82) | 54 (40.91) | 12 (31.58) | 0.298 |
Lung consolidation, n(%) | 121 (71.18) | 92 (69.70) | 29 (76.32) | 0.427 |
Vasoactive drugs, n(%) | 98 (57.65) | 63 (47.73) | 35 (92.11) | <.001 |
Albumin, n(%) | 124 (72.94) | 89 (67.42) | 35 (92.11) | 0.003 |
Hormones, n(%) | 98 (57.65) | 78 (59.09) | 20 (52.63) | 0.478 |
IVIG, n(%) | 110 (64.71) | 91 (68.94) | 19 (50.00) | 0.031 |
ECMO, n(%) | 3 (1.76) | 0 (0.00) | 3 (7.89) | 0.010 |
Ventilator, n(%) | 155 (91.18) | 117 (88.64) | 38 (100.00) | 0.064 |
High frequency ventilation, n(%) | 11 (6.47) | 7 (5.30) | 4 (10.53) | 0.436 |
Invasive ventilation, n(%) | 142 (83.53) | 107 (81.06) | 35 (92.11) | 0.106 |
Exchange transfusion, n(%) | 39 (22.94) | 23 (17.42) | 16 (42.11) | 0.001 |